In 2012, Antibiotice posted a net profit of RON27 million, 33% higher year-on-year.
The company expects total revenue of RON339 million in 2013, up 5% on the year, while overall costs are seen increasing at a similar pace to RON304.4 million.
Exports are forecast to rise 17%, from $20 million in 2012.
Antibiotice is majority held by Romania’s Health Ministry, with a 53% stake, while investment fund SIF Oltenia (SIF5.RO) owns a 10% stake.
On the Bucharest bourse Thursday, Antibiotice closed up 1.1% at RON0.46 a share, amid a slightly declining market. (EUR1=RON4.4281)